Abstract
Objective: To develop a core outcome set for endometriosis. Design: Consensus development study. Setting: International. Population: One hundred and sixteen healthcare professionals, 31 researchers and 206 patient representatives. Methods: Modified Delphi method and modified nominal group technique. Results: The final core outcome set includes three core outcomes for trials evaluating potential treatments for pain and other symptoms associated with endometriosis: overall pain; improvement in the most troublesome symptom; and quality of life. In addition, eight core outcomes for trials evaluating potential treatments for infertility associated with endometriosis were identified: viable intrauterine pregnancy confirmed by ultrasound; pregnancy loss, including ectopic pregnancy, miscarriage, stillbirth and termination of pregnancy; live birth; time to pregnancy leading to live birth; gestational age at delivery; birthweight; neonatal mortality; and major congenital abnormalities. Two core outcomes applicable to all trials were also identified: adverse events and patient satisfaction with treatment. Conclusions: Using robust consensus science methods, healthcare professionals, researchers and women with endometriosis have developed a core outcome set to standardise outcome selection, collection and reporting across future randomised controlled trials and systematic reviews evaluating potential treatments for endometriosis. Tweetable abstract: @coreoutcomes for future #endometriosis research have been developed @jamesmnduffy.
| Original language | English |
|---|---|
| Pages (from-to) | 967-974 |
| Number of pages | 8 |
| Journal | BJOG: An International Journal of Obstetrics and Gynaecology |
| Volume | 127 |
| Issue number | 8 |
| Early online date | 30 Mar 2020 |
| DOIs | |
| Publication status | Published - Jul 2020 |
Bibliographical note
Funding InformationCatalyst Fund
Endometriosis Millennium Fund
Funding
MLH has received travel grants from Merck‐Serono and Geurbet, research funding from AbbVie, Merck, Origio, and Myovant, and has been a consultant to Vifor Pharma. AWH has received consultancy fees from AbbVie, Ferring, Nordic Pharma, and Roche Diagnostics. NPJ has received conference expenses from Bayer Pharma, Merck‐Serono, and Merck and Co., research funding from AbbVie, and has been a consultant to Guerbet, Mvovant Sciences, and Vifor Pharma. LR has received research funding from Ferring Australia, Merck‐Serono, and MSD, and chairs the Ferring Australia advisory board. The remaining authors report no competing interests. Completed disclosure of interests form available to view online as supporting information. This study was funded by the Catalyst Fund, the Royal Society of New Zealand, and Endometriosis Millennium Fund, Royal College of Obstetricians and Gynaecologists. The funders had no role in the design and conduct of the study, the collection, management, analysis, or interpretation of the data, or preparation of the article.
Keywords
- Consensus development study
- core outcome set
- endometriosis
- modified Delphi method
- modified nominal group technique
- Prospective Studies
- Humans
- Endometriosis
- Consensus
- Delphi Technique
- Research Personnel
- Health Personnel
- Endpoint Determination
- Biomedical Research
- Female
- Research Design